Protalix BioTherapeutics (PLX) Reports Q1 Loss of $0.05
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.39 --0%
Revenue Growth %: -49.8%
Financial Fact:
COST OF REVENUES: -4.25M
Today's EPS Names:
CCEL, FNGR, FAST, More
Revenue Growth %: -49.8%
Financial Fact:
COST OF REVENUES: -4.25M
Today's EPS Names:
CCEL, FNGR, FAST, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q1 EPS of ($0.05). Revenue for the quarter came in at $16.1 million versus the consensus estimate of $15.5 million.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- IBM (IBM) PT Raised to $350 at Oppenheimer
- IBM misses Q2 targets as mainframe and software sales disappoint
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
